Macaca mulatta
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA297766 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Transcriptome Profiling in KY1005-treated NHP HCT-recipients
| PRJNA389177 | ENA
Project description:Transcriptome Profiling in KY1005-treated NHP HCT-recipients
| PRJNA476948 | ENA
Project description:Transcriptome Profiling in tissues and blood from NHP-HCT Recipients
| PRJNA1193598 | ENA
Project description:Aging is a major risk factor for various forms of disease. An enhanced understanding of the physiological mechanisms related to aging is urgently needed. Nonhuman primates (NHPs) have the closest genetic relationship to humans, making them an ideal model to explore the complicated aging process. Multiomics analysis of NHP peripheral blood offers a promising approach to evaluate new therapies and biomarkers. Here, we explored the mechanisms of aging using proteomics (serum and serum-derived exosomes [SDEs]) in rhesus monkey (Macaca mulatta) blood.
2024-06-22 | PXD030287 | Pride
Project description:Aging is a major risk factor for various forms of disease. An enhanced understanding of the physiological mechanisms related to aging is urgently needed. Nonhuman primates (NHPs) have the closest genetic relationship to humans, making them an ideal model to explore the complicated aging process. Multiomics analysis of NHP peripheral blood offers a promising approach to evaluate new therapies and biomarkers. Here, we explored the mechanisms of aging using proteomics (serum) in rhesus monkey (Macaca mulatta) blood.
2024-06-22 | PXD030289 | Pride
Project description:Graft versus host disease (GVHD) is the most common complication of hematopoietic stem cell transplant (HCT). However, our understanding of the molecular pathways that cause this disease remains incomplete, leading to inadequate treatment strategies. To address this, we measured the gene expression profile of non-human primate (NHP) T cells during acute GVHD (GSE73723). Within these profiles we discovered potentially druggable targets not previously implicated in GVHD, prominently including aurora kinase A (AURKA). In this study, we performed a planned comparison of AURKA gene expression in HCT-recipients with clinical GVHD and compared it to expression in HCT-recipients without clinical GVHD.
2015-11-29 | GSE73809 | GEO
Project description:Gene expression of lung tissues in non-human primate (NHP, rhesus macaque) after exposure to thoracic irradiation
| PRJNA289999 | ENA
Project description:Rapid CD137 upregulation on alloreactive T-cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody-drug conjugate (CD137-ADC) administered on the day of transplant without additional immunosuppression. The CD137-ADC depleted both human and non-human primate (NHP) activated T-cells and proved highly effective in preventing xenogeneic aGVHD in mice receiving human peripheral blood mononuclear cells (PBMC), as well as in NHP undergoing MHC-haploidentical HCT. Flow cytometry analysis of NHP T-cells indicated specific depletion of activated PD-1+ CD4 and CD8 T-cells, while sparing naïve and PD-1-OX40+ memory T-cell subsets during the first week after HCT. CD137-ADC-treated NHP recipients demonstrated robust hematopoietic and immune reconstitution. Hallmarks of T-cell recovery after CD137-ADC, which were associated with long-term aGVHD-free survival, included reconstitution of CD4 memory T-cells expressing TRAIL, terminally-differentiated CD8 T-cells expressing CX3CR1, and CD4 FoxP3+ Tregs – cell types not expected to be involved in aGVHD pathogenesis. CD137-ADC-treated recipients demonstrated a higher risk of reactivation of rhLCV (the rhesus macaque EBV analogue), which was associated with reconstitution of follicular helper T-cells, interferon signaling-associated memory, and gamma-delta T-cell subsets. This reactivation was controllable with rituximab administration. These results document effective depletion of alloreactive T-cells and prevention of aGVHD following a single dose of CD137-ADC, suggesting that clinical translation should be carefully explored.
2025-05-28 | GSE298063 | GEO
Project description:The purpose of the experiment was to compare placental transcriptome of rhesus macaque at approximately 80% completed gestation to human placental transcriptomes.
2018-08-09 | GSE118284 | GEO
Project description:Rapid CD137 upregulation on alloreactive T-cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody-drug conjugate (CD137-ADC) administered on the day of transplant without additional immunosuppression. The CD137-ADC depleted both human and non-human primate (NHP) activated T-cells and proved highly effective in preventing xenogeneic aGVHD in mice receiving human hematopoietic stem cell grafts, as well as in NHP undergoing MHC-haploidentical HCT. Flow cytometry analysis of NHP T-cells indicated specific depletion of activated PD-1+ CD4 and CD8 T-cells, while sparing naïve and PD-1-OX40+ memory T-cell subsets. CD137-ADC-treated NHP recipients demonstrated robust hematopoietic and immune reconstitution. Hallmarks of T-cell recovery after CD137-ADC, which were associated with long-term aGVHD-free survival, included reconstitution of CD4 memory T-cells expressing TRAIL, terminally-differentiated CD8 T-cells expressing CX3CR1, and CD4 FoxP3+ Tregs – cell types not expected to be involved in aGVHD pathogenesis. CD137-ADC-treated recipients demonstrated a higher risk of reactivation of rhLCV (the rhesus macaque EBV analogue), which was associated with reconstitution of follicular helper T-cells, interferon signaling-associated memory, and gamma-delta T-cell subsets. This reactivation was controllable with rituximab administration. These results document effective depletion of alloreactive T-cells and prevention of aGVHD following a single dose of CD137-ADC, suggesting that clinical translation should be carefully explored.
2025-05-27 | GSE298158 | GEO